VIDEO: Osimertinib plus chemotherapy may benefit some lung cancer subsets
Click Here to Manage Email Alerts
Osimertinib plus chemotherapy may benefit some lung cancer subsets compared with osimertinib alone, according to recent research from the FLAURA2 trial.
The research, presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, found that patients with EGFR-mutated advanced NSCLC who received osimertinib (Tagrisso, AstraZeneca) plus chemotherapy had improved PFS compared to those who received osimertinib alone.
“It seemed that patients with baseline [central nervous system] disease, baseline brain metastases, actually probably got the most benefit from the addition of chemotherapy, but we’re still waiting on some of the other subgroup analyses such as baseline co-mutations” Melina Elpi Marmarelis, MD, medical director of the Penn Mesothelioma Program and an assistant professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania, told Healio.
She noted that while the overall survival data was not mature at the time of the presentation, the available OS data did not demonstrate a significant difference between those who received osimtertinib plus chemotherapy and those who received osimertinib alone.
“I don’t think this will be universally adopted over osimertinib alone, which is a very well-tolerated and affective treatment, so we’ll be looking to the additional subgroup analyses to see who might benefit from this approach,” she said.
Collapse
Jänne PA, et al. Abstract PL03.13. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer; Sept. 9-12, 2023; Singapore.
Read more about
Click Here to Manage Email Alerts